Browsing Tag
RUCONEST
2 posts
Pharming expands Joenja into children as rare-disease growth offsets RUCONEST pressure
Pharming has secured FDA approval for Joenja in children aged four to 11 weighing at least 27 kg, widening a rare-disease franchise whose quarterly revenue grew 40% while RUCONEST declined.
Why Joenja’s pediatric expansion could strengthen Pharming Group’s long-term commercial runway
Find out how Pharming’s Joenja FDA review could affect PHAR stock sentiment, pediatric APDS access, and rare-disease revenue growth.